Cargando…

Pharmacogenetics of novel glucose-lowering drugs

The aim of this work was to review studies in which genetic variants were assessed with respect to metabolic response to treatment with novel glucose-lowering drugs: dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathmann, Wolfgang, Bongaerts, Brenda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099830/
https://www.ncbi.nlm.nih.gov/pubmed/33594477
http://dx.doi.org/10.1007/s00125-021-05402-w